Oxacillin Inj Rx
Generic Name and Formulations:
Oxacillin sodium 1g/vial, 2g/vial, 10g/vial; pwd for IM or IV inj after reconstitution, or IV drip after reconstitution and dilution; sodium content 2.5mEq/g oxacillin sodium.
Various generic manufacturers
Indications for Oxacillin Inj:
Susceptible infections due to penicillinase-producing staphylococci.
Give by IM gluteal inj, or slow IV inj over 10 mins, or IV drip. Mild-to-moderate infections: 250–500mg IM or IV every 4–6 hours. Severe infections: 1g IM or IV every 4–6 hours; treat for at least 14 days, then continue for at least 48 hours after becoming afebrile, asymptomatic, or (–) cultures. Endocarditis or osteomyelitis: may need longer therapy; see literature. Switch to oral therapy as soon as clinically indicated.
Give by IM gluteal inj, or slow IV inj over 10 mins, or IV drip. Premature and neonates: 25mg/kg/day IM or IV. Infants and children <40kg: Mild-to-moderate infections: 50mg/kg/day IM or IV in divided doses every 6 hours; severe infections: 100mg/kg/day IM or IV in divided doses every 4–6 hours; treat for at least 14 days, then continue for at least 48 hours after becoming afebrile, asymptomatic, or (–) cultures. Endocarditis or osteomyelitis: may need longer therapy; see literature. Switch to oral therapy as soon as clinically indicated.
Cephalosporin or other allergy: not recommended. Asthma. Renal impairment: consider dose reduction. Do CBCs, BUN, urinalysis, creatinine levels prior to and weekly during therapy. Monitor renal, hepatic and hematopoietic function in prolonged use. Elderly (esp. IV route). Newborns (monitor). Pregnancy (Cat.B). Nursing mothers.
May be antagonized by tetracycline; avoid. Potentiated by probenecid.
Inj site reactions, rash, serum sickness, GI upset, anaphylaxis, neuropathy, nephropathy, blood dyscrasias, hepatotoxicity.
Formerly known under the brand name Bactocill.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC